This is a unique opportunity to play a key role in shaping CESPE’s vision for sustainable, agile manufacturing of the medicines of the future. We are looking for a manager to join our team and drive forward the vision of our platform uniting 20 research groups and numerous industry partners.
Do you know someone that might be a good fit for this role, with industry and team management experience? Please feel free to forward this role to them!
Last month’s 𝐂𝐄𝐒𝐏𝐄 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 was a great success, and we want to extend our sincere thanks to everyone who contributed -whether by presenting, attending, or supporting the event. We were delighted by the high-quality presentations and the range of inspiring, forward-looking topics that sparked meaningful discussions throughout the day.
𝗪𝗵𝗮𝘁 𝗮𝗻 𝗶𝗻𝘀𝗽𝗶𝗿𝗶𝗻𝗴 𝗱𝗮𝘆 𝗮𝘁 𝘁𝗵𝗲 𝟰𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗖𝗘𝗦𝗣𝗘 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗶𝗻 𝗚𝗵𝗲𝗻𝘁 𝘆𝗲𝘀𝘁𝗲𝗿𝗱𝗮𝘆! We brought together brilliant minds from academia, industry, and regulatory fields to explore the future of pharmaceutical manufacturing, personalized medicine, and sustainability.
We extend our sincere thanks to all speakers, partners, and participants for their valuable contributions to an inspiring and forward-looking conference. The 𝗣𝗮𝗻𝗲𝗹 𝗗𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 on 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘯𝘨 𝘈𝘐 𝘪𝘯 𝘱𝘩𝘢𝘳𝘮𝘢 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘪𝘰𝘯 𝘴𝘦𝘵𝘵𝘪𝘯𝘨 stood out as particularly engaging!
The programme for CESPE Conference is now complete and the schedule is online! Check out the event’s programme and don’t miss the talks by speakers from industry and academia, including representatives from UCB, J&J, SimAbs, Gericke, Legend Biotech, Antleron, and UGent. Our event will take place on 22nd of October at RodeBol Events venue in Ghent!
We also proudly announce that the topic of our Panel Discussion this year will be on ‘Regulatory Hurdles Regarding the Use of AI in Pharmaceutical Production Setting‘! Be ready to dive into the challenges of regulating AI in pharmaceutical manufacturing and listen in on the opinions of expert AI solutions providers, pharmaceutical companies, and regulatory bodies!
Our annual CESPE Conference on the 22nd of October is approaching fast and we are looking forward to gathering with the members of our community for this event! The event’s programme is full of exciting speakers from industry and academia, including UCB, SimAbs, Gericke, Legend Biotech, Antleron, and UGent, with more announcements on the way.
Due to an exceptional amount of students in the interuniversity master of Industrial Pharmacy, we are looking for additional companies willing to host students for the master’s thesis program.
In the presentation below, you will find a description of the master’s thesis program (based on Project Oriented Learning – POL) in more detail. In addition, the presentation lists some important timelines and deadlines. A virtual information session will be organized for all companies that offer a POL project this year. This information session will take place on Monday 22 September 2025 at 10.30 am. Participating companies will receive dial-in details some time in advance. This virtual session will also be recorded, and the recording will be made available.
In case of interest, please define and specify the POL topics by August 31st, 2025 using the Word template and send it to Thomas.DeBeer@UGent.be. These descriptions will then be presented to the ManaMa Industrial Pharmacy students.
Don’t hesitate to contact Thomas De Beer (Thomas.DeBeer@UGent.be) with any further questions.
The preliminary programme for our yearly CESPE Conference has now been published on our website. The event is filled with engaging talks from industrial as well as academic speakers and provides ample networking opportunities. Don’t miss your chance to catch speakers from UCB, Legend Biotech, simAbs, Gericke, Antleron, and UGent, as they discuss the current developments and challenges in sustainable pharmaceutical manufacturing.
Browse the three conference sessions below and stay tuned for future announcements as we are working to confirm the last few speakers to complete our programme.
With the opening scheduled for 31 December 2025, The Nucleus is on its way to becoming a vibrant hub for groundbreaking R&D and sustainable innovation at Tech Lane Ghent Science Park. But is more than just a workspace—it is a community. With state-of-the-art facilities, including event spaces, catering services, and versatile meeting rooms.
As a key tenant, CESPE will occupy a significant part of the facility – an investment that underlines the ambition to position the Ghent region as a global hotspot for manufacturing innovation in the (bio)pharma sector.
This vision is made possible by the strength of the ecosystem within Tech Lane Ghent Science Park: a unique combination of academic research, industrial leadership and technological excellence. With direct connections to research institutions, e.g. VIB, imec, and international companies, e.g. J&J, Legend Biotech, Sanofi. This is the place to be for opportunity, growth, innovation and connection.
From this new base, CESPE will also continue to support talent development through the CESPE Academy, which offers a wide range of training programs.
Stay tuned as opening day approaches: The Nucleus is more than a building; it is a catalyst for the future!
Ghent-Gosselies, May 27, 2025 – The EU Biotech Campus and CESPE (Centre of Excellence for Sustainable Pharmaceutical Engineering and Manufacturing) are proud to announce a new strategic partnership. This collaboration is rooted in our shared ambition to equip the biotech & biopharmaceutical work force with future-proof skills and raise awareness about the importance of talent development in the life sciences sector.
Together, we will engage in joint communication efforts to highlight key challenges and opportunities in biotech and pharmaceutical training, and to connect industry stakeholders with relevant learning pathways.
“This partnership with CESPE is perfectly aligned with our mission to create the most dynamic and inclusive biotech training ecosystem in Belgium and in Europe. By joining forces, we are amplifying our impact and inspiring the next generation of talent.” Sabrina Ena, CEO of the EU Biotech Campus
“We are delighted to embark on this partnership with EU Biotech Campus. It is a powerful step towards a future where talent and innovation are central. This partnership plays a crucial role in nurturing talent and encouraging continuous innovation that reflects the spirit of Belgium’s thriving (bio)pharma ecosystem.”Christoph Portier, General Manager of CESPE
This marks the beginning of a strategic dialogue between two institutions committed to supporting the growth of biotech and pharmaceutical ecosystems through knowledge-sharing and training.
Stay tuned for joint initiatives that will spotlight skills development, innovation, and collaboration in life sciences.
About EU Biotech Campus
EU Biotech Campus is a training hub based in the Biopark in Gosselies, Charleroi (Belgium) — in the heart of the Wallonia Health Tech Valley. Opening in end 2025, the 5,500 m² facility will offer state-of-the-art spaces and programs to develop talent in the biotechnology, biopharmaceutical and health sectors. As a multi-operator and innovation-driven ecosystem, EU Biotech Campus offers a unique environment where immersive, state-of-the-art training programs meet the real-world needs of companies and learners alike. Our approach combines hands-on learning, advanced technology exposure, and interdisciplinary knowledge exchange with training programs focusing on biomanufacturing processes, digital transition, advanced therapies, soft skills, and STEM awareness, equipping participants with the future-proof competencies needed to thrive in the life sciences industry.
Ghent University (UGent) is a top 100 university and one of the largest Belgian universities in the heart of Europe, renowned for its national and international educational, scientific and industrial cooperation. UGent TechTransfer and the platforms such as CESPE, support researchers in transferring groundbreaking science to bring innovations to the market.
Through the multidisciplinary approach and collaboration with both academic and industrial partners, CESPE contributes to the development of innovative, sustainable and flexible production processes for the medicines of the future.
Next to its research activities, one of the core values of CESPE is providing talent & skills for the (bio)pharmaceutical industry. CESPE wants to achieve this by bringing together the broad expertise of its diverse academic and industrial members. Over the years, each of these members built extensive knowledge, through both academic research or industrial collaborations. Therefore, CESPE actively promotes knowledge sharing across the (bio)pharmaceutical value chain. This commitment, alongside the demand from the (bio)pharmaceutical industry, led to the creation of the CESPE Academy, which offers a wide range of basic and specialized courses tailored to both industrial and academic professionals.
At the end of this year, CESPE will relocate to ‘The Nucleus’, the new landmark building at Tech Lane Ghent Science Park. This strategic move places CESPE and the Academy at the heart of the pharmaceutical ecosystem and increases its proximity to leading research institutes and international companies. The new location provides a unique environment that fosters collaboration, encourages innovation and expands opportunities for advanced training.
We are pleased to announce that registrations for our fourth edition of the annual CESPE conference on ‘Scaling sustainable (Bio)Pharmaceutical Manufacturing’ have been opened.
For registrations before September 15th 2025, the Early Bird attendance fees are €300.-/€400.- for industry (CESPE-member/non-member) and €75.-/€125.- for academic (CESPE-member/non-member) participants. The Early Bird fee for participants from governmental or non-profit organizations is €125.-.
For the networking dinner, a supplement of €75 is charged.
The deadline for registration is October 20th.
Information on sponsorships and exhibition booths can be found here.
Are you ready to play a pivotal role in shaping the future of pharmaceutical engineering and manufacturing? The Centre of Excellence in Sustainable Pharmaceutical Engineering & Manufacturing (CESPE) at Ghent University is seeking an Operational Manager to drive our ambitious goals forward.
Our Mission
CESPE, a collaboration between 20 research groups at Ghent University Association and industrial partners, aims to lead the way in sustainable (bio)pharmaceutical manufacturing innovations. As our Operational Manager, you will work closely with the CESPE Director, General Manager, Project Managers, and Communication Officer to support our objectives and diverse range of activities.
Key Responsibilities
You coordinate the CESPE Academy, proactively developing a range of workshops, webinars, and other offerings that meet the needs of industrial partners. You also interact with both internal and external instructors.
In close collaboration with the core team, you actively contribute to expanding the project portfolio of involved researchers and partner companies.
You help engage CESPE researchers when potential opportunities arise (e.g., Flemish & European project calls, bilateral contract research, and services).
Together with the General Manager, you ensure the financial management of CESPE and the core facilities.
You share responsibility for interactions with industrial partners and ensure the continuity of partnerships.
You are responsible for setting up and expanding new strategic research fields, such as mechanochemistry, particle engineering, and automation.
You contribute to CESPE’s visibility through tasks including:
Leading the Communication Officer
Structuring the CESPE Conference and smaller events
Representing CESPE at (inter)national congresses
You work with the team to develop a future-proof operational strategy for the daily operations of the research facilities at the CESPE Innovation Accelerator.
Your Profile
You hold a Master’s or Doctoral degree based on a dissertation in the fields of (bio-)engineering sciences, pharmaceutical sciences, veterinary medicine, or chemistry, or have equivalent experience.
You have strong knowledge of and interest in the scientific domains within CESPE.
You possess solid project management skills, are well-organized, and ensure timely delivery within budget.
Knowledge of the technical requirements of a high-tech pharmaceutical production environment is an asset.
You are driven and have the ambition to help develop a world-class expertise center in sustainable pharmaceutical production in collaboration with the team.
You are familiar with or have experience in working with universities and industrial actors, such as (bio)pharmaceutical companies (a relevant network is an advantage).
Experience in developing public-private project proposals is an asset.
You have strong communication skills (both verbal and written) in at least English and Dutch.
You are a team player who can work independently and in a structured manner within a complex organization.
With a “get things done” attitude, you manage and follow up on your tasks and delegated assignments effectively.
What We Offer
We provide a 2 year contract, offering stability and opportunity for growth within our dynamic team.
Salary is determined according to scales WM1 to WM4 (for Master’s degree holders) or PD1 to PD4 (for Doctoral degree holders). More information about our salary scales is available.
Additionally, all Ghent University employees can benefit from a range of advantages, such as extensive training and development opportunities, 36 vacation days per year (for full-time positions), a bicycle allowance, eco vouchers, and more. A full overview of our employee benefits is available.
Ready to Make an Impact?
If you’re excited about contributing to the forefront of sustainable pharmaceutical engineering and manufacturing, we want to hear from you! Join us at CESPE and be part of a collaborative effort to shape the future of pharmaceutical innovation. Apply now to seize this opportunity to drive meaningful change in the industry.
We are thrilled to announce the official launch of the ambitious PHARMECO project, co-funded by the Innovative Health Initiative Joint Undertaking (IHI JU). This groundbreaking initiative aims to transform pharmaceutical industry to more sustainable pharmaceutical manufacturing practices by integrating environmentally-friendlier technologies, improved processes and standardized sustainability assessment methods.
PHARMECO will address the production of small molecules, tides, biologics, and medical devices & technologies, with a key focus on:
Sustainable-by-Design (SSbD) platforms for early-stage pharmaceutical development
Green processes for industrial-scale manufacturing and decontamination
Advanced digital tools for sustainability assessment and decision-making
CESPE is excited to lead this alliance of 31 esteemed international partners, together with Sanofi as industry project lead:
CESPE’s focus on sustainable innovation in drug manufacturing positions it as the ideal coordinator for this groundbreaking six-year project, guiding partners toward ambitious sustainability goals. Seven Ghent University research groups, all CESPE members, will be actively involved across all PHARMECO workstreams:
The Sustainable Systems Engineering group (STEN) (Prof. Jo Dewulf, Lieselot Boone) will lead the workstream on sustainable design and evaluation frameworks for pharmaceuticals, collaborating closely with Johnson & Johnson and Sanofi. Supported by Ghent University’s Epidemiology of Chronic Diseases unit (Prof. Delphine De Smedt), the Biovism Lab (Prof. Jan Verwaeren), the Bionamix Lab (Prof. Paul Van Liedekerke), and several international partners, STEN will lead environmental impact assessments for innovative manufacturing technologies , the set-up of holistic sustainability evaluations, and development of models and digital tools for predictive sustainability, with industry input to enhance scalability and precision.
The Synthesis, Bioresources, and Bio-organic Chemistry group (SynBioC) (Prof. Chris Stevens) will contribute to the workstream on sustainable chemical synthesis. SynBioC’s activities will focus on creating intermediates from bio-renewable sources, using non-precious metal catalysts, utilizing high-throughput experimentation tools, which will contribute to the project’s ambition to implement cleaner, more economical chemical synthesis processes in industry practice.
The Pharmaceutical Engineering Research Group (Prof. Ashish Kumar) and the Laboratory of Pharmaceutical Process Analytical Technology (Prof. Thomas De Beer) will both contribute to the workstream focused on intensification of biomanufacturing processes. Their efforts will centre on implementing advanced model-based strategies for process control and optimizing production processes. These activities will support the workstream’s objective to incorporate scalable, cleaner, and resource-efficient biomanufacturing methods, practices, and unit operations into industry standards.
Stay tuned for updates as we work on adopting more sustainable practices in pharmaceutical manufacturing!
We are pleased to announce a significant milestone in the development of The Nucleus, the future home of the CESPE Innovation Accelerator, located at the Tech Lane Ghent Science Park. The structural works have reached their highest point, marking a pivotal step in this landmark project.
In keeping with the Meiboomviering tradition, and with a festive touch, this achievement was commemorated by placing a Christmas tree atop the structure. This gesture symbolizes growth, celebration, and the promise of what is to come.
We extend our deepest gratitude to our valued construction partners for their dedication and collaboration throughout this process: PMV, POM Oost-Vlaanderen, Sogent, Ghent University, Algemene Bouw Maes nv, evr-architecten, VK architects+engineers (part of Sweco), and VINCI Energies.
As The Nucleus takes shape, it is set to become an important center for innovation and collaboration at Tech Lane Ghent Science Park. We look forward to sharing more updates as the project progresses.
Join Ghent University as a Professor in Biologics Manufacturing!
CESPE/Ghent University is excited to announce an open, full-time Lecturer (Tenure Track) position in the Faculty of Bioscience Engineering, Department of Biotechnology, specializing in Biologics Manufacturing.
If you’re passionate about innovative, applied, and multidisciplinary research in biopharmaceutical process technology, this opportunity might be for you! This role emphasizes large-scale production of biopharmaceuticals and biotherapeutics, addressing the global need for efficient, profitable production and final product processing.
On Monday, June 1st, we had the pleasure of hosting a hardware session in collaboration with our partner, Comate. We were thrilled to have two inspiring speakers:
• Thomas De Beer, CEO of RheaVita, who has integrated all freeze-drying process steps into a continuous production line with a constant infeed of products and the concomitant outfeed of the dried product.
• Leander Van Neste, CEO of Axithra, who is developing a platform to quickly and accurately measure and monitor therapeutic drug concentrations in blood.
Both leaders shared valuable lessons learned and the challenges they’ve faced in their growth journeys. They addressed questions such as the TRL of the product at the moment of the spinoff, the major technological challenges to become GMP/IVD/MDR compliant, and the steps taken in terms of customer/problem/solution fit during the first year.
Their engaging presentations were followed by a lively Q&A session. The event concluded with an opportunity to network and digest the insights over drinks and bites.
We are thrilled to announce that CESPE will be coordinating a groundbreaking €41 million flagship project, PharmECO – Advancing Safe and Sustainable by Design Practices in Pharmaceutical Manufacturing, of which the proposal has now officially been approved! This pioneering initiative, co-funded under the Innovative Health Initiative (IHI JU Call 4, Topic 6), aims to revolutionize pharmaceutical manufacturing by (i) implementing cutting-edge, sustainable, and scalable manufacturing technologies, and (ii) establishing harmonized environmental sustainability assessment systems for pharmaceuticals and biopharmaceuticals.
To achieve the ambitious goals of this project, 7 CESPE research groups will collaborate with 30 esteemed international institutes, including universities, research institutes, governmental bodies, SMEs, and major pharmaceutical companies.
PharmECO is set to kick off on October 1st, 2024.
CESPE groups involved:
Prof. Jo Dewulf – Sustainable Systems Engineering (STEN) research group; Faculty of Bioscience Engineering
Prof. Chris Stevens – Synthesis, Bioresources and Bio-organic Chemistry Research Group (SynBioC); Faculty of Bioscience Engineering
Prof. Ashish Kumar – Pharmaceutical Engineering Research Group; Faculty of Pharmaceutical Sciences
Prof. Thomas De Beer – Laboratory of Pharmaceutical Process Analytical Technology Faculty of Pharmaceutical Sciences
Prof. Delphine Desmedt Department of Public Health and Primary Care; Faculty of Medicine and Health Sciences
Prof. Paul van Liedekerke – BionamiX Research Unit, Department of Data analysis and mathematical modelling, Faculty of Bioscience Engineering
Prof. Jan Verwaeren – KERMIT research unit, Department of Data analysis and mathematical modelling Faculty of Bioscience Engineering
Looking Ahead:
As we embark on this exciting journey, we are committed to driving innovations that will not only advance pharmaceutical manufacturing but also contribute to a more sustainable future. Stay tuned for updates on our progress and the incredible developments we will bring to the industry.
We at CESPE were thrilled to attend the official opening of the HighTru Lab. This innovative facility marks a significant milestone as Belgium’s first academic lab capable of high-throughput experimentation (HTE), accelerating chemical and pharmaceutical discoveries.
HTE technology enables the simultaneous conduction and rapid analysis of numerous experiments, for example, by using 96-well plates. By leveraging miniaturization, automation, and advanced data management systems, HTE can efficiently screen vast amounts of chemical space. This approach facilitates the discovery of optimal conditions or novel reactions.
The state-of-the-art equipment of HighTru includes solid and liquid handling robots, a robotic reaction platform with integrated solid and liquid handling, several reaction platforms for high-pressure, photo-, and electrochemistry, a high-throughput UPLC-MS, and a software platform for HTE design, execution, and data analysis. This equipment operates under an open-access model, facilitating collaboration between industry and academia. This remarkable partnership, involving Ghent University, Johnson & Johnson, and the City of Ghent, with funding from the EU Recovery and Resilience Facility, will accelerate research and strengthen Ghent’s reputation as a hub for cutting-edge science.
Join our Industrial Member Secoya at a two-day crystallization event!
During this event, you’ll have the exclusive opportunity to discover Secoya’s continuous crystallization technology, explore their latest technological breakthroughs, meet their experts, dive into research and industrial case studies and network with fellow enthusiasts.
Last but not least, Secoya will seize the opportunity to showcase the whole new SCT family, from lab to industrial unit.
Ghent (October 5th, 2023) – It is with great pleasure that Pfizer Puurs and Ghent University (UGent) announce that Pfizer has officially joined the CESPE innovation cluster, a multi-partner innovation accelerator in the field of pharmaceutical engineering and manufacturing.
We are proud of our footprint in Belgium and our worldwide impact, and happy to expand it further through this collaboration with CESPE at Ghent University. As we continue to innovate and improve our manufacturing processes and expertise, it is critical that we collaborate with the best and brightest, and we are confident the team at CESPE has the right expertise to make this partnership a great match.
Gudrun Coppens, Director Manufacturing Science & Technology at Pfizer Puurs
The close collaboration between industry and academia in this strategic partnership, combined with their drive to innovate, will play a key role in future pharmaceutical manufacturing.
We are thrilled to welcome Pfizer Puurs to our fast-growing CESPE community of leading innovators in (bio)pharmaceutical manufacturing. We are excited to embark on this inspiring collaborative journey with Pfizer Puurs . This partnership also plays a pivotal role in nurturing local talent and fostering a culture of continuous innovation reflecting the spirit of the thriving Belgian pharma/biotech ecosystem, and particularly the flourishing region of Flanders .
Dr. Dominic De Groote, Business Development Manager at CESPE
Copyright Pfizer
About Pfizer Puurs
Pfizer Manufacturing Belgium is the largest production and packaging site of Pfizer worldwide, specializing in aseptic production and packaging. The Pfizer Puurs facility covers 100.000m², and manufactures more than 400 million units of injectable medicines and vaccines every year (excl. Comirnaty). The product physiology ranges from sterile solutions, to sterile suspensions, sterile gels, and freeze dry products, all packed on site in ampoules, vials, plastic bottles, syringes, or cartridges for pens. The medicines and vaccines made in Puurs are shipped to patients in more than 170 markets. 30% of Puurs production is destined for low income countries, in collaboration with UNICEF, WHO, GAVI, and NGOs.
The site has an extensive manufacturing setup with a range of formulation booths, filling lines, automatic inspection lines, packaging lines, freeze driers, and lab facilities. With their clinical pilot plant and experimental plant the Pfizer Puurs is also known as a Launch Site within the Global Pfizer network, providing them the ability to quickly scale-up to commercial manufacturing of a new product. The last 10 years the number of employees in Puurs has more than doubled, bringing the total number of employees to more than 4.500 in 2023.
Ghent University (UGent) is a top 100 university and one of the largest Belgian universities in the heart of Europe. It is an active partner in national and international educational, scientific and industrial cooperation. The organization is committed to research and innovation with an annual research budget of more than € 600 million and more than 5,500 researchers active in a wide range of the life, physical and social sciences. UGent TechTransfer and the UGent Business Development Platforms, such as CESPE, support researchers in developing groundbreaking science to bring innovations to the market.
The Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE) is a multidisciplinary innovation accelerator hosted at Ghent University focusing on the sustainable development, design and optimization of both drug substance and drug product production platforms. Its ambition is to become the reference centre in end-to-end (bio)pharmaceutical manufacturing in Europe. It accelerates the development of emerging production technologies to manufacture the medicines of the future in a sustainable, agile way.
Leading global professional services company, Cognizant, and the Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE) have today announced a partnership which will accelerate the realization of innovative, sustainable, and agile developments in the pharmaceutical sector, at large scales.
The partnership will focus on knowledge sharing and prototyping ground-breaking ideas across various industry related topics, such as industry 4.0 and maximizing the value of Digital Twins in R&D and manufacturing by hybrid modelling, with use of the latest advanced analytical methods. Cognizant will also become a CESPE Industrial Member, joining the growing community where academic researchers and industrial partners are connected and where they can exchange information on sustainable pharmaceutical engineering and manufacturing at multiple levels.
Both Cognizant and CESPE’s main goal is to reinvent the pharmaceutical and biopharmaceutical industry: Cognizant as a technology partner and CESPE as complementary research center. CESPE is a multidisciplinary innovation accelerator hosted at Ghent University focusing on the sustainable development, design and optimization of both drug substance and drug product production platforms. Ghent University (UGent) is a top 100 university and one of the largest Belgian universities in the heart of Europe. It is an active partner in national and international educational, scientific, and industrial cooperation. CESPE’s ambition is to become the reference center in end-to-end (bio)pharmaceutical manufacturing in Europe. It accelerates the development of emerging production technologies to manufacture the medicines of the future in a sustainable, agile way. Cognizant implements, integrates, operationalizes, and scales such innovations within the life sciences industry, while contributing to similar ground-breaking innovative ideas with resourceful individuals working for Cognizant with various skills and rich domain knowledge. Conversely, CESPE can apply Cognizant’s patented technological solutions in examining and prototyping their own research.
“We at Cognizant are incredibly excited to partner with a leading institute like CESPE. Together, we are going to make significant strides in the development of technologies like digital twins in the pharmaceutical industry. This will make companies, and the overall industry, much more flexible and effective, thus stimulating innovation. We are proud to be doing our part to support the significant life sciences industry in Belgium, which has huge impact both locally and beyond.”
Gregory Verlinden, Associate Vice President of Analytics & AI at Cognizant
“We are actively looking for partnerships that endorse our core values. Cognizant’s complementary nature is exactly what we are looking for: a balanced collaboration with a reciprocal knowledge exchange. Our collaboration starts with the digital twin but can certainly expand later.”
Bram Bekaert, Operational Manager at CESPE
Find out more about Cognizant on their webpage: https://www.cognizant.com/
Ghent University is now accepting applications for our Master of Science in Pharmaceutical Engineering (MPE) program. Our program offers a unique combined training of pharmaceutical and engineering skills. Both skills are required to develop these pharmaceutical production processes for tomorrow’s drug products and supply needs. The MPE consists of a two-year English-taught programme of 120 credits and will help you acquire all skills and knowledge that you need to implement novel manufacturing concepts that require a high degree of digitalization and automation. The MPE will also increase your opportunities to get a good position in the pharmaceutical industry or to become an excellent PhD candidate!
It is with great honour that we can announce professor Dieter Deforce as a new academic member of CESPE. His expertise in the fields of pharmaceutical biotechnology and (forensic) DNA-analysis are a crucial addition to the CESPE portfolio.
Dieter Deforce is a professor at the University of Ghent and is the head of the Laboratory of Pharmaceutical Biotechnology at the Faculty of Pharmaceutical Sciences. From 2001 till 2016 he was also head of the forensic DNA‐analysis laboratory, which he founded at the University of Ghent, accredited and recognized by the Belgian government. He remains in the forensic field as dedicated DNA expert.
He is chair of the Belgian Medicines Committee, member of the Scientific Advise Working Party of the European Medicines Agency. He is also the director of the ProGenTomics platform of the University of Ghent, providing amongst others proteomics and mainly mass spectrometry based protein analytical tools to the research community. He is a partner in NXT‐GNT, a research consortium providing the research community next generation DNA‐sequencing. He is member of the board of directors of the VIB.
His research focuses on applying proteomics and genomics platforms (including Next Generation Sequencing) in the field of post translational protein modifications, stem cell development, prenatal genetic diagnosis, (auto‐)immunity and forensics and he is (co‐)author of over 350 scientific papers.
On September 15, we hosted our first conference on Manufacturing Innovations for a Sustainable (Bio)Pharmaceutical Industry. We were thrilled to have more than 120 participants from over 40 different companies, who were able to enjoy our diverse program with ample networking opportunities. If you couldn’t make it or would like to relive the day, have a look at our aftermovie to take in some of the innovative atmosphere we witnessed that day!
We are excited to announce that professor Hristo Svilenov has joined CESPE as an academic member. With the onboarding of prof. Svilenov, we further strengthen our capabilities in the field of biopharmaceutical manufacturing.
Hristo Svilenov is a professor of biopharmaceutical manufacturing technology and formulation in the Laboratory of General Biochemistry and Physical Pharmacy at Ghent University. Before moving to Ghent, he was postdoc with Prof. Johannes Buchner at the Technical University of Munich funded by a fellowship from the Peter und Traudl Engelhorn Foundation and a grant from the Else Kröner-Fresenius Foundation. From 2016 to 2019, he did his PhD sponsored by a Maria Skłodowska-Curie fellowship in the group of Prof. Gerhard Winter at the University of Munich. For his research, Dr. Svilenov received several prizes like the Carl Wilhelm Scheele Award from the German Pharmaceutical Society (DPhG) or the Abbvie Award for the best doctoral thesis. He is a pharmacist by training.
Hristo Svilenov is working on different aspects of the development, manufacturing, and formulation of biotherapeutics. A strong research focus is on the application of novel analytical techniques and biophysical methods to design better therapeutic proteins and formulations.
9h30 Welcome & conference opening Rik Van de Walle, Rector UGent
9h40 Introduction to CESPE Prof. Thomas De Beer, CESPE Director
10h00 Flanders R&D policies for better health and care – Towards Recovery Resilience Kathleen D’Hondt, Policy Analyst, Department Economy, Science and Innovation – Flemish Government
10h15 Keynote ‘Healthcare Innovation: the crossroads of HealthTech and the (bio)pharmaceutical ecosystem’ Ann Van Gysel, CEO Medvia
10h45 Break (posters & exhibition booths)
Chemical drug substance manufacturing of the future
11h05 Drug Substance Manufacturing in 2030 – adaptive, connected & sustainable Yves Vancleemput, Director Business Development, Janssen Pharmaceutica
11h20 The Future will flow, more and more in the pharmaceutical sector Prof. Chris Stevens, UGent
11h35 Design of Sustainable Pharmaceutical Processes with Artifcial Intelligence Maarten Dobbelaere, UGent
Biopharmaceuticals: a fast growing pipeline
11h50 Setting up a large scale clinical and commercial CAR-T manufacturing HUB in Ghent Birk Vanderweeën, General Manager Europe, Legend Biotech
13h25 Continuous manufacturing of antibodies: the inevitable step towards sustainable drug manufacturing Koen Dierckx, CEO SimAbs
13h40 Discovery and selection of therapeutic antibodies with drug-like properties Prof. Hristo Svilenov, UGent
13h55 An academic’s journey to spin-out commercialization of a new manufacturing technology: continuous pharmaceutical lyophilization Prof. Thomas De Beer, UGent & RheaVita
Towards efficient Drug Product Development & Controlled Manufacturing
14h10 Challenges and opportunities in drug product development Fanny Stauffer, Drug Product Expert, UCB
14h30 Linking material proporties to their behavior during processing Prof. Chris Vervaet, UGent
Process simulation & sustainable systems engineering as key element for future proof pharmaceutical manufacturing
14h45 Advanced process simulation for smart manufacturing process development, scale-up and operation Wim Audenaert, CEO & Co-founder AM-Team
15h00 Sustainability Assessment in the pharmaceutical sector dr. Lieselot Boone, UGent
15h15 Break (posters & exhibition booths)
(Bio)pharmaceutical manufacturing; staying ahead of what’s next
15h45 Panel discussion Ann Van Gysel, CEO Medvia Claire Skentelbery, Director General EuropaBio Yves Vancleemput, Director Business Development, Janssen Pharmaceutica Birk Vanderweeën, General Manager Europe, Legend Biotech Prof. Thomas De Beer, CESPE Director (moderation: Tineke Van hooland)
16h30 Pech Kucha presentations
Closing
17h45 Closing word Sofie Bracke, Executive Councillor for Economy, Port and Sports, City of Ghent
Wouter De Soete, Manager CESPE Christoph Portier, CESPE Operations Manager
Networking reception & Dinner
18h00 – 22h00 (posters & exhibition booths)
On this page you will find all the updates considering the program of our CESPE conference on Manufacturing Innovations for a Sustainable (Bio)Pharmaceutical Industry. At this event, there will be a mix of senior industry leaders, policy makers, academics and startups. There will be a variety of talks on chemical drug substance, drug product and biotech manufacturing, providing insights in both industrial and academic state-of-the-art. There will also be ample opportunities to network with all participants.
What’s in it for you? You will:
Have access to state-of-the-art science in the field of chemical drug substance, drug product and biotech manufacturing
Get to know groundbreaking and disruptive manufacturing technologies
Expand your professional network
Learn more about our new facilities planned at Tech Lane Ghent Science Park, including cleanrooms to handle potent APIs
Have the latest insights in the new Master in Pharmaceutical Engineering, unique in Flanders and launched in September ’22.
Have discussion opportunities with talented PhD and postdoctoral researchers through interactive poster sessions
Learn about access to young talent through various master thesis opportunities
We are excited to announce Dr. Ann Van Gysel as keynote speaker at our CESPE Conference on Manufacturing Innovations for a Sustainable (Bio)Pharmaceutical Industry on September 15th in Ghent! Dr. Van Gysel was recently appointed as CEO of the spearhead cluster MEDVIA. In her keynote, she will focus on the current trends in healthcare and the (bio)pharmaceutical landscape.
Ann Van Gysel has always been passionate about innovation in healthcare. She started out as a biologist and received her PhD in molecular biology from the University of Gent. She acquired post-graduate degrees in Business Management and Marketing and Communications. In 2009, she joined FlandersBio as Managing Director. During her three-year tenure, she doubled the number of members, putting Flanders on the international map as a one of the major biotech hubs. In 2011, Ann founded Turnstone Communications, a consultancy agency providing communications and marketing services to healthcare, life sciences and pharmaceutical organizations in Belgium and abroad. She was the founder of the digital life sciences news platform BioVox.eu, sharing Belgian innovations with national and international professionals. Since January 2022 she has been the CEO of MEDVIA, a public-private partnership founded by the Flemish Government to support innovation in healthcare focusing on biotech, medtech and digital health.
CESPE is pleased to announce its yearly conference on Thursday September 15, 2022 focusing on Manufacturing Innovations for a Sustainable (Bio)Pharmaceutical Industry. This event will cover both drug substance and drug product manufacturing innovations, demonstrating the position of Flanders and Belgium as global leaders in (bio)pharmaceutical manufacturing. During this physical event in Ghent, you will have the opportunity to network with our academic members, industrial partners and policy makers. Therefore, this event is perfectly suited for senior scientists, industrial decision makers and policy makers active within the ecosystem.
Stay tuned for more information on the program and registration!
2 PhD Positions to develop a Predictive Framework enabling Real-Time Release Testing in Solid Dosage Manufacturing
Overview
This PhD project aims to develop a knowledge-based predictive framework for dissolution testing to enable real-time release testing (RTRt) in solid dosage manufacturing. The research will be conducted in close cooperation with pharmaceutical companies and the UGent research accelerator Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE). The research outcome will be published in important scientific journals.
Traditionally, RTRt frameworks are developed by individual companies and partnering research institutions leading to a costly and resource-intensive process. Moreover, the development requires a thorough process understanding as well as controls embedded in the production processes. In this project, a predictive framework for dissolution testing will be developed using material, process, and PAT data from continuous direct compression process. This project presents a unique opportunity to work at the academia-industry interface on a very important and relevant topic to the pharmaceutical industry. A range of formulations and knowledge from multiple pharmaceutical companies involved in the project will lead to development of a generic and better predictive framework enabling RTRt.
The project currently has two open positions for PhD candidates: a PhD project with an Experimental focus and a PhD project with a mathematical modeling focus. The researcher with an experimental focus will get an in-depth scientific understanding, hands-on experience of direct compression based manufacturing and gain expertise in practical aspects of dissolution test development applicable to an industrial working environment. The researcher with a modeling focus will apply different modeling approaches of developing in vitro predictive dissolution models based on product and process understanding. Hence, a predictive dissolution modeling framework will be developed to support product development within the space explored during formulation and process optimization and as surrogate tests in a regulatory filing towards RTRt.
Profiles
Experimental research focus:
Master’s degree in pharmaceutical sciences, physical chemistry, or a related discipline
Experience in dissolution testing of pharmaceutical dosage forms.
Experience with various analytical techniques (DSC, XRD, IR, TGA, DVS, HPLC).
Experience in multivariate data analysis is desirable.
Mathematical modeling research focus:
Master’s degree in bioengineering, chemical engineering, and process engineering or a related discipline
Experience with the development of numerical methods
Experience with mechanistic and data-driven modeling methodologies
Experience in Python and/or MATLAB is desirable.
Candidates must have a strong interest in both experiments and theoretical modeling
More information For further information, please contact:
You have to use the online application tool available here or by sending an email to Ashish.Kumar@UGent.be to provide your CV with names of three references, motivation letter and transcripts of your bachelor and master studies.
Application deadline and start date
The position is available immediately and will remain open until it is filled. While the start date is flexible, the target is to start from Feb 2022.
2 PhD positions in Pharmaceutical Manufacturing Innovation with Focus on Continuous Pharmaceutical Freeze-Drying
Overview
The general goal of these PhD research projects is to further innovate in a continuous freeze-drying technology for (bio)pharmaceuticals and explore its potential as an enabler for different pharmaceutical products.
Topic 1: The evaluation of different energy supply systems for the continuous & controlled (mechanistic based) freeze-drying of biopharmaceutical unit doses.
Topic 2: Continuous freeze-drying as an enabling technology for different types of pharmaceutical products (e.g., lipid nano-particle based products, highly concentrated protein formulations, vaccines, cold chain distributed products, etc.) The research projects may be conducted in close cooperation between Ghent University (Belgium) and pharmaceutical companies and equipment manufacturers. The PhD project will be executed in Ghent, Belgium. The research outcome will be published in important scientific journals.
Profile
Master’s degree in Pharmaceutical Drug Development, Industrial Pharmacy, Pharmaceutical Engineering, Bio-science Engineering, Chemical Engineering or a related discipline.
Experience with pharmaceutical technology is desirable.
Candidates must have a strong interest in biopharmaceutical product development manufacturing innovation, analysis and data-analysis.
Pharmaceutical Process Analytics & Technology research group (Ghent University) Faculty of Pharmaceutical Sciences Prof. Dr. T. De Beer – Thomas.DeBeer@UGent.be – +32-9-2648097
How to apply
Please send your CV with names of three references, motivation letter and transcripts of your bachelor and master studies to Thomas.DeBeer@UGent.be
Belgium has an excellent position in the development of new medicines. ‘To continue to play that leading role, we also need to focus on innovation in drug production,’ says Professor Thomas De Beer.
With the CESPE Innovation Accelerator, Ghent University offers an answer to the need for top research infrastructure for innovation in pharmaceutical production technology. This is necessary to further anchor Belgium’s leading position in the field of drug development research and to guarantee its production in our region.
Need for innovation in pharmaceutical production
‘If you look at pharmaceutical manufacturing innovation over the last decades, it hasn’t kept up with the speed of drug development. Innovation in the pharmaceutical sector primarily focuses on the development of medicines. But the increasing complexity of medicines and their supply needs also requires innovation in production technology,’ says Professor Thomas De Beer. He is director of CESPE, the Center of Excellence for Sustainable Pharmaceutical Engineering & Manufacturing at Ghent University, which is the basis of the new innovation accelerator for production technology in the pharmaceutical sector.
‘Innovation in the pharmaceutical sector primarily focuses on the development of medicines. But the increasing complexity of medicines and their supply needs also requires innovation in production technology.’ Professor Thomas De Beer.
‘Unlike other sectors in the manufacturing industry, pharmaceutical products are often developed before it is clear how they can be produced on a large scale in a competitive, sustainable and flexible way. By linking the development of a medicine at an early stage to the development of the production process, you shorten the lead time,’ explains Professor De Beer.
‘The Corona pandemic has also increased the need for agile production technologies. Just think of the supply of intermediate substances in the event of an abruptly rising demand or local production of critical medicines, and the associated cold chain distribution at -80°C of certain vaccines. This requires new technologies and we will research and develop them in the new CESPE center in collaboration with the industry,’ says Wouter De Soete, manager of CESPE at Ghent University.
Unique research infrastructure
The CESPE Innovation Accelerator will include cleanrooms, lab and office space as well as a (bio)pharmtech incubator. ‘This combination of research infrastructure in the field of production innovation is unique in Belgium. With this we make a huge difference, not only for academic research but also for industry,’ emphasizes Professor De Beer.
‘This research infrastructure in the field of production innovation is unique in Belgium. With this we make a huge difference, not only for academic research but also for industry.’ Professor De Beer.
There are strict requirements for the production of medicines. You have to create the right conditions for researchers and for the products you work with. Thanks to the modular and flexible layout of the cleanrooms and lab areas, large companies, start-ups and research institutions can perform tests and collaborate under optimal conditions. This is the only way to create the right environment for innovation.’
The center also provides the necessary space to accommodate spin-offs resulting from this innovative research. ‘We strongly believe that cross-fertilization between industry and academia will lead to innovative production technologies. In the field of production technology within the pharmaceutical sector, we want to become the reference point, both for research and training of the right profiles. For that reason, we will start with a new master in pharmaceutical engineering in the academic year 2022-2023. This combination of pharmaceutical and engineering skills is much needed in the sector to realize innovation. By focusing on that, we are firmly convinced that this will lead to new start-ups. We also want to offer them the necessary support in the CESPE center to start up and grow.’
‘The main goal of CESPE is to be the leading innovation hub in Europe for the end-to-end pharmaceutical production of tomorrow’s medicines,’ according to Wouter De Soete. ‘That means that we examine the entire drug production chain, from development to its supply to the market, and examine how we can model and optimize it as best as possible. For this we have to call on different expertise. Just think of experts in the field of big data, AI, automation and robotization, energy-efficient production,…’ According to De Soete, the center in Zwijnaarde will be a game changer for the pharmaceutical industry in Flanders, which will also provide a lot of jobs.
Ghent (March 25, 2021) – Takeda and Ghent University (UGent) are pleased to announce that Takeda’s Global Manufacturing Site at Lessines has officially joined the CESPE innovation cluster, a multi-partner innovation accelerator in the field of pharmaceutical engineering and manufacturing. This strategic partnership reflects both parties’ strong desire to further intensify their research and innovation efforts and to make optimal use of the cross pollination between industry and academia. Initially, this partnership will focus on optimising digitization in Pharma 4.0, pharmaceutical technology innovation, and optimising energy and material efficiency during production.
“As one of the global leaders in the production of plasma derivatives, Takeda continuously improves its manufacturing operations. To this end, the mutual sharing of knowledge with other companies and knowledge institutions like CESPE is key”
— Gert Verheyden, Head of Manufacturing Sciences at Takeda Lessines —
“As one of the global leaders in the production of plasma derivatives, Takeda continuously improves its manufacturing operations. To this end, the mutual sharing of knowledge with other companies and knowledge institutions like CESPE is key”, says Gert Verheyden, Head of Manufacturing Sciences at Takeda Lessines. “This allows Takeda Lessines to make a significant contribution to the training of tomorrow’s pharmaceutical engineers, both in existing and emerging education tracks, and also to increase the industrial relevance of possible innovation projects at the international level.” “We are thrilled to collaborate with Takeda and to thus facilitate its strong desire to implementing innovative production processes of active pharmaceutical ingredients and finished pharmaceutical products. We are collaborating precompetitively with an industrial network to build a strong knowledge region enabling the local anchoring of talent and innovation”, says professor Thomas De Beer, Director of CESPE.
Copyright Takeda
About Takeda
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.
Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
Ghent University (UGent) is a top 100 university and one of the largest Belgian universities in the heart of Europe. It is an active partner in national and international educational, scientific and industrial cooperation. The organization is committed to research and innovation with an annual research budget of more than € 600 million and more than 5,500 researchers active in a wide range of the life, physical and social sciences. UGent TechTransfer and the UGent Business Development Platforms, such as CESPE, support researchers in developing groundbreaking science to bring innovations to the market.
The Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE) is a multidisciplinary innovation accelerator hosted at Ghent University focusing on the sustainable development, design and optimization of both drug substance and drug product production platforms. Its ambition is to become the reference centre in end-to-end (bio)pharmaceutical manufacturing in Europe. It accelerates the development of emerging production technologies to manufacture the medicines of the future in a sustainable, agile way.
Great job opportunity! Want to develop your Process Development Engineering skills? Our partner simAbs, developing a new biopharmaceutical manufacturing platform, might have just the challenge you’re looking for! Check out the job offer here!
Did you miss any of the presentations during the CESPE Industrial Partnering Day 2020? Review them here! Full stream available!
Welcome
Rik Van de Walle, Ghent University, Rector
Sofie Bracke, City of Ghent, Alderman for Economy, Trade, Sport & Port
Introduction to CESPE
Introduction to CESPE (Wouter De Soete, CESPE Manager)
Keynote “Belgian Biotech: Evolution & Revolution”
Geoffrey Pot, Chairman of the Board Bio.be/essenscia, Takeda Site Head, VP Operations
Industry Testimonial: Janssen Pharmaceutica
Jan Van der Goten, Head of Strategic Campus Office, Janssen Pharmaceutica
Research and Innovation pitches
Prof. Chris Stevens, Microreactor Technology: One Flow, One Product
Prof. Thomas De Beer, Prof. Ingmar Nopens, The Future of Pharmaceutical Drug Product Manufacturing
Prof. Richard Hoogenboom, Poly(2-oxazoline)s as Novel Excipients for Oral Formulations
Prof. Ludwig Cardon, 3D Printing: An Innovative Manufacturing Method
Prof. Kevin Van Geem, Maarten Dobbelaere, Artificial Intelligence for Computer-Aided Synthesis in Flow
Prof. Joris Thybaut, Chemical Reactor Performance Assessment and Innovation by Modeling
Prof. Jo Dewulf, Sustainability Assessment in Pharmaceutical Manufacturing
Prof. Dieter Claeys, Jeroen De Maeyer, Industry 4.0 Operational Excellence for Pharma 4.0
Company pitches
Koen Dierckx, simAbs, CEO, Integrated Continuous Bioprocessing of Monoclonal Antibodies
https://vimeo.com/492092157
Pieter-Jan Van Bockstal, RheaVita, Project Manager Technology, A Continuous Freeze-Drying Technology for Fast, Flexible and High Quality Manufacturing of Biopharmaceutical Products
SAVE THE DATE for the first CESPE Industrial Partnering Day! December 2nd, 2.00pm – 5.00pm Feel free to forward within your organisation
Interested in how Ghent University accelerates innovation and cultivates partnerships in Sustainable Pharmaceutical Engineering and Manufacturing? Innovating in the pharmaceutical or biotech industry? Equipment, infrastructure developer or system integrator? We gladly introduce you to CESPE and provide you with a selection of high-quality R&I pitches from both UGent and industry!
Speakers:
UGent rector Rik Van de Walle
Deputy mayor of the City of Ghent Sofie Bracke
World class industry leaders: Janssen Pharmaceutica and Takeda.
Register now to receive your personal invite and program updates on the Keynote and pitching sessions!
Free of charge. Registration is closed.
End-to-end integrated pharmaceutical manufacturability of tomorrow’s medicines – Enabling sustainable innovation in drug substance and drug product production.
Fascinated by pharmaceutical process development and how novel drug manufacturing techniques contribute to that? Eager to pursue a PhD in Pharmaceutical Sciences on the industrial implementation of continuous tablet manufacturing via direct compression?
This could be your opportunity! A collaboration between Ghent University CESPE and Johnson and Johnson Belgium!
More information on the topic and how to apply on the UGent Job portal!
Short project description
The pharmaceutical industry is switching from batch-wise to continuous manufacturing of tablets. The aim of current project is to address crucial gaps of knowledge for industrial implementation of continuous tablet manufacturing via direct compression.
During drug product development limited amounts of new chemical entities are available to investigate the effect of formulation and process variables on the final drug product. The first aim is therefore to develop a strategy for identification of a surrogate component, i.e. a component with similar characteristics as the new chemical entity, to use during early process and formulation development trials. Furthermore, continuous feeding of very cohesive raw materials is often challenging and affects further downstream processing. Therefore, various formulation strategies to overcome feeding issues of very cohesive raw materials in function of process parameters will be developed. Finally, a control strategy based on residence time distributions is of utmost importance to ensure the final product quality and traceability along the manufacturing line. Therefore, the critical formulation and process parameters affecting residence time distributions on a continuous direct compression line will be investigated and predictive models will be built for each unit operation and for the integrated line.
Interested in the capabilities of continuous freeze-drying? What is the impact on stability, supply chain, manufacturing operations, quality control, etc.?
Subscribe to the hands-on workshop on batch versus continuous freeze-drying of pharmaceuticals!
Demonstration of continuous freeze-drying prototypeF
Formulation characterization for batch and continuous freeze-drying hands-on training
DEMO PAT for continuous freeze-drying
Dynamic design space determination
Execution of batch and continuous freeze-drying processes for selected formulations
Evaluation performed batch and continuous freeze drying runs
Determination CQAs freeze-dried products: batch versus continuous
CESPE will present to you at Knowledge for Growth 2018 this week Thursday 17th in Ghent #KfG2018! Visit us at exhibition booth 75, first floor of TTO Flanders Ghent University Tech Transfer to get to know more about the Centre of Excellence in Sustainable Pharmaceutical Engineering. #KfG2018 with flanders.bio. https://www.knowledgeforgrowth.be/
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
